Trade Cytokinetics Inc - CYTK CFD
Add to favourite- Summary
- Historical Data
Spread | 0.18 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024207% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 50.88 |
Open | 51.21 |
1-Year Change | 50.4% |
Day's Range | 50.22 - 51.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 9, 2024 | 50.41 | -0.29 | -0.57% | 50.70 | 51.41 | 50.15 |
Dec 6, 2024 | 50.88 | 0.53 | 1.05% | 50.35 | 51.89 | 50.11 |
Dec 5, 2024 | 50.35 | 0.64 | 1.29% | 49.71 | 50.59 | 49.52 |
Dec 4, 2024 | 50.38 | -0.71 | -1.39% | 51.09 | 51.43 | 50.26 |
Dec 3, 2024 | 51.39 | 1.11 | 2.21% | 50.28 | 51.74 | 49.91 |
Dec 2, 2024 | 50.56 | 0.04 | 0.08% | 50.52 | 51.47 | 50.22 |
Nov 29, 2024 | 51.80 | -0.15 | -0.29% | 51.95 | 52.65 | 51.59 |
Nov 27, 2024 | 52.20 | 0.45 | 0.87% | 51.75 | 52.76 | 51.47 |
Nov 26, 2024 | 51.94 | 2.36 | 4.76% | 49.58 | 52.65 | 49.38 |
Nov 25, 2024 | 50.16 | 0.80 | 1.62% | 49.36 | 50.99 | 49.30 |
Nov 22, 2024 | 49.01 | 1.50 | 3.16% | 47.51 | 49.74 | 47.35 |
Nov 21, 2024 | 47.58 | -2.37 | -4.74% | 49.95 | 50.26 | 47.54 |
Nov 20, 2024 | 49.81 | -0.68 | -1.35% | 50.49 | 50.78 | 49.54 |
Nov 19, 2024 | 51.02 | 0.02 | 0.04% | 51.00 | 51.55 | 49.60 |
Nov 18, 2024 | 51.88 | 1.71 | 3.41% | 50.17 | 51.95 | 49.45 |
Nov 15, 2024 | 50.19 | -4.61 | -8.41% | 54.80 | 54.86 | 49.74 |
Nov 14, 2024 | 54.67 | -1.19 | -2.13% | 55.86 | 56.19 | 54.41 |
Nov 13, 2024 | 55.91 | -0.64 | -1.13% | 56.55 | 57.61 | 55.90 |
Nov 12, 2024 | 56.14 | -2.14 | -3.67% | 58.28 | 58.80 | 56.02 |
Nov 11, 2024 | 58.58 | 0.55 | 0.95% | 58.03 | 59.30 | 57.79 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cytokinetics Inc Company profile
About Cytokinetics, Inc.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cytokinetics, Inc. revenues increased 26% to $70.4M. Net loss increased 69% to $215.3M. Revenues reflect License revenues increase of 50% to $54.9M, Milestone revenues increase of 79% to $5M. Higher net loss reflects Research and development increase of 66% to $149.5M (expense), Other General and administrative increase of 91% to $80.4M (expense).
Equity composition
Common Stock $.001 Par, 02/11, 170M auth., 66,910,100 o/s. Insiders and Straegic holds 9.82%. 4/29/04, 5,800,000 shares @ $13 per share by Goldman, Sachs & Co. 25/13, 1-for-6 Reverse Stock split.
Industry: | Bio Therapeutic Drugs |
350 Oyster Point Boulevard
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
09:32, 4 December 2024Silver price forecast 2025 and beyond: Third party price target
Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?
16:00, 3 December 2024Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
16:41, 28 November 2024Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com